Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
23.88
+0.37 (1.57%)
At close: Aug 21, 2026, 4:00 PM EDT
24.02
+0.14 (0.59%)
After-hours: Aug 21, 2026, 7:45 PM EDT

Tango Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
53.8162.3842.0736.5324.8637.04
Revenue Growth
121.48%48.29%15.17%46.93%-32.89%383.83%
Gross Profit
-79.84-69.78-101.85-78.67-81.05-40.59
Operating Income
-136.35-111.29-145.6-114.17-111.07-58.19
Net Income
-123.72-101.59-130.3-101.74-108.18-58.24
Earnings Per Share
-0.91-0.87-1.19-1.08-1.23-0.94
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,014343.14257.92336.89366.13485.26
Total Debt
31.9933.5736.4938.9241.131.5
Net Cash (Debt)
982309.57221.42297.97325483.75
Net Cash Growth
573.63%39.81%-25.69%-8.32%-32.82%165.16%
Net Cash Per Share
7.262.662.033.153.707.79

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-143.9-138.89-131.5-117.98-109.08-59.53
Capital Expenditures
-0.37-1.05-0.75-1.53-7.69-1.84
Free Cash Flow
-144.27-139.93-132.26-119.51-116.77-61.36
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-148.37%-111.86%-242.10%-215.38%--109.59%
Operating Margin
-253.38%-178.39%-346.09%-312.57%-446.79%-157.09%
Pretax Margin
-230.03%-162.85%-309.24%-278.18%-434.92%-156.43%
Profit Margin
-229.92%-162.85%-309.73%-278.55%-435.14%-157.21%
FCF Margin
-268.10%-224.31%-314.38%-327.18%-469.72%-165.66%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
74.8319.137.8927.6425.7225.86